<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320726">
  <stage>Registered</stage>
  <submitdate>21/10/2009</submitdate>
  <approvaldate>23/10/2009</approvaldate>
  <actrnumber>ACTRN12609000915257</actrnumber>
  <trial_identification>
    <studytitle>Do the post operative nausea and vomiting (PONV) drugs Granisetron and Ondansetron negate the analgesic effects of Paracetamol?</studytitle>
    <scientifictitle>Do the post operative nausea and vomiting (PONV) drugs Granisetron and Ondansetron negate the analgesic effects of Paracetamol in healthy male volunteers?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Analgesia</healthcondition>
    <healthcondition>Post operative nausea and vomiting</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Volunteers will be cannulated and a baseline pain threshold measured using a "PainMatcher". Volunteers will receive either Granisetron 1mg intravenously (iv), ondansetron 4mg intravenously (iv) or 5mls normal saline intravenously (iv) (placebo). 30 minutes later (time T 0) pain threshold will be measured followed by administration of paracetamol 1g intravenously (iv) and decannulation. Pain thresholds will be measured at T30, T60, T120, T180 and T240 using the "PainMatcher".  The trial is fully randomised and double blinded.  Each volunteer will attend 3 clinical sessions spaced one week apart so that they receive all three medications in a crossover fashion.</interventions>
    <comparator>Normal saline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain threshold as a indication of the analgesic effect of paracetamol - measured using the "PainMatcher"</outcome>
      <timepoint>Baseline pain threshold 
Pain thresholds at 0 mins (T0), 30 mins (T30), 60 mins (T60), 120 mins (T120), 180 mins (T180), 240 mins (T240)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy male volunteers aged 18 to 55 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Female, minors, known hypersensitivity to one of the drugs, excessive caffeine consumption (&gt; 4 cups coffee per day), excessive cigarette smoking, illicit drugs, concomitant use of prescription medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4814 - Townsville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Paul Sherwin</primarysponsorname>
    <primarysponsoraddress>Chief Researcher
The Townsville Hospital
100 Angus Smith Drive
Douglas
Qld
4814</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Townsville Hospital Foundation</fundingname>
      <fundingaddress>The Townsville Hospital
100 Angus Smith Drive
Douglas 
Qld 4814</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Sancha Robinson</sponsorname>
      <sponsoraddress>Associate Researcher
The Townsville Hospital
100 Angus Smith Drive
Douglas
Qld
4814</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>12/11/2009. A pilot study checking the sensitivity of the Painmatcher is currently underway. This involves 20 healthy male volunteers who are randomised to receive either 100mls Normal Saline intravenously or 1g Paracetamol intravenously in a blinded crossover fashion. Pain thresholds are checked using the PainMatcher at T0, T30, T60, T120, T180, T240.  Each volunteer has been trained four times prior to the first clinical session in the use of the PainMatcher.

18/07/2010. The pilot study has now been completed.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Townsville Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>The Townsville Hospital
100 Angus Smith Drive
Douglas
Qld
4814</ethicaddress>
      <ethicapprovaldate>10/09/2009</ethicapprovaldate>
      <hrec>HREC/09/QTHS/67</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Paul Sherwin</name>
      <address>The Townsville Hospital
100 Angus Smith Drive
Douglas
Qld
4814</address>
      <phone>+61 437 701838</phone>
      <fax />
      <email>paul_sherwin@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sancha Robinson</name>
      <address>The Townsville Hospital
100 Angus Smith Drive
Douglas
Qld
4814</address>
      <phone>+61 428 771849</phone>
      <fax />
      <email>sanchasd@yahoo.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sancha Robinson</name>
      <address />
      <phone>+61 428 771849</phone>
      <fax />
      <email>sanchasd@yahoo.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>